Marksans Pharma to Acquire 100% Stake in Netherlands-Based QliniQ B.V. for €7.5 Million
Marksans Pharma to Acquire 100% Stake in Netherlands-Based QliniQ B.V. for €7.5 Million Read Post »
Includes all shareholder-related actions such as dividends, bonus issues, stock splits, buybacks, and rights issues. These announcements directly impact shareholder value and stock price adjustments.